Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

February 28, 2014

Conditions
Retinal DiseaseMacular Disease
Interventions
DRUG

Interferon gamma-1b

"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Eye Institute (NEI)

NIH

NCT01468337 - Topical Interferon Gamma-1b for Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter